Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 20 of 23 for “"Sample size re-estimation"”.

  1. Sample size re-estimation in active controlled non-inferiority clinical trials using a frequentist approach

    … hypothesis that the experimental treatment is therapeutically not inferior to the active control within a pre-defined margin. At the design stage, the misspecification of any design parameters (e.g., the variance or treatment difference for continuous endpoints, control event rate …

    bu Repository record for Sample size re-estimation in active controlled non-inferiority clinical trials using a frequentist approach (opens in a new tab)

  2. Sample Size Re-Estimation for Confirmatory Two-Stage Multi-Arm Trials With Normal and Binary Outcomes

    Multi-arm clinical trials comparing several treatments against a common control are more efficient than traditional multiple two-arm trials. Several flexible multi-arm designs which utilize the closed test procedure for strong familywise error rate control have been proposed to allow treatment …

    uab Repository record for Sample Size Re-Estimation for Confirmatory Two-Stage Multi-Arm Trials With Normal and Binary Outcomes (opens in a new tab)

  3. Evaluation Of Sample Size Re-Estimation Procedures For Non-Inferiority Designs With Time-To-Event Outcomes

    Study designs that allow sample size review may potentially save a study by identifying misspecified assumptions, modifying the planned sample size, and reinforcing the study’s power. Most sample size re-estimation (SSR) methods in non-inferiority trials have been developed for continuous or binary …

    uab Repository record for Evaluation Of Sample Size Re-Estimation Procedures For Non-Inferiority Designs With Time-To-Event Outcomes (opens in a new tab)

  4. An Evaluation Of Sample Size Re-Estimation Adaptive Designs And Delayed-Start Designs For Alzheimer'S Disease Trials

    … and to provide applications for their use in real trials. The data used for our simulation is a meta-data base of completed trials. In the first paper, we investigate the sample size re-estimation (SSR) adaptive design based on the effect size and the variance without taking into account the …

    uab Repository record for An Evaluation Of Sample Size Re-Estimation Adaptive Designs And Delayed-Start Designs For Alzheimer'S Disease Trials (opens in a new tab)

  5. A BAYESIAN DECISION THEORETIC APPROACH TO FIXED SAMPLE SIZE DETERMINATION AND BLINDED SAMPLE SIZE RE-ESTIMATION FOR HYPOTHESIS TESTING

    This thesis considers two related problems that has application in the field of experimental design for clinical trials: • fixed sample size determination for parallel arm, double-blind survival data analysis to test the hypothesis of no difference in survival functions, and • blinded sample size …

    temple Repository record for A BAYESIAN DECISION THEORETIC APPROACH TO FIXED SAMPLE SIZE DETERMINATION AND BLINDED SAMPLE SIZE RE-ESTIMATION FOR HYPOTHESIS TESTING (opens in a new tab)

  6. Integrated Multiple Adaptive Design Involving Sample Size Re-Estimation and (Covariate-Adjusted) Response-Adaptive Randomization for Continuous and Binary Outcomes

    … designs have been developed to provide increased flexibility, allowing pre-specified changes to occur based on interim data. Each adaptive design addresses a unique pitfall of a non-adaptive design, such as minimizing the chance of an under- or over-powered study by utilizing interim data …

    vcu Repository record for Integrated Multiple Adaptive Design Involving Sample Size Re-Estimation and (Covariate-Adjusted) Response-Adaptive Randomization for Continuous and Binary Outcomes (opens in a new tab)

  7. Sample size re-estimation for superiority clinical trials with a dichotomous outcome using an unblinded estimate of the control group outcome rate

    Superiority clinical trials are often designed with a planned interim analysis for the purpose of sample size re-estimation (SSR) when limited information is available at the start of the trial to estimate the required sample size. Typically these trials are designed with a two-arm internal pilot …

    bu Repository record for Sample size re-estimation for superiority clinical trials with a dichotomous outcome using an unblinded estimate of the control group outcome rate (opens in a new tab)

  8. An approach to conditional power and sample size re-estimation in the presence of within-subject correlated data in adaptive design superiority clinical trials

    … the design of a clinical trial based on interim results is sample size re-estimation (SSR). SSR allows an increase in the trial's sample size in order to maintain, at the desired nominal level, the desired power to reject the null hypothesis conditioned on the interim observed treatment effect …

    bu Repository record for An approach to conditional power and sample size re-estimation in the presence of within-subject correlated data in adaptive design superiority clinical trials (opens in a new tab)

  9. Methods in subgroup analysis: estimation of risk and implications for randomized controlled trial design

    Estimation of exposure-specific risks (ESRs) using estimates of the overall risk and relative risk of disease given exposure has been performed in previous studies, but the performance of such an estimator has not been assessed nor has a variance for such an estimate been proposed. In this project …

    bu Repository record for Methods in subgroup analysis: estimation of risk and implications for randomized controlled trial design (opens in a new tab) Embargoed until 2999-01-01

  10. Issues in Group Sequential/Adaptive Designs

    In recent years, there has been great interest in the use of adaptive features in clinical trials (i.e., changes in design or analyses guided by examination of the accumulated data at an interim point in the trial) that may make the studies more efficient (e.g., shorter duration, fewer patients). …

    penn Repository record for Issues in Group Sequential/Adaptive Designs (opens in a new tab)

  11. Calculating power for the Finkelstein and Schoenfeld test statistic

    … composite endpoints (e.g., components are assessed in order of clinical importance). Power and sample size estimation for the FS test, however, are generally done via simulation studies. This simulation approach can be extremely computationally burdensome, compounded by an increasing …

    bu Repository record for Calculating power for the Finkelstein and Schoenfeld test statistic (opens in a new tab)

  12. New approach to compare treatments in adaptive seamless designs while maintaining Type I error and ensuring adequate power

    … Phase II clinical trials, we often compare the efficacy of several doses of an experimental product versus a control group (often a placebo). We then use the results from the Phase II to design the subsequent confirmatory superiority Phase III trial, and we use statistical methods in the …

    bu Repository record for New approach to compare treatments in adaptive seamless designs while maintaining Type I error and ensuring adequate power (opens in a new tab)

  13. Power Issues And Internal Pilot Designs For Cluster-Randomized Trials With Unequal Cluster Sizes

    … themselves, run the risk of being underpowered when they are designed assuming equal cluster sizes but end up recruiting unequal clusters. The loss in power of the trial is directly related to the amount of variation present among the cluster sizes. To overcome the loss in power, researchers …

    uab Repository record for Power Issues And Internal Pilot Designs For Cluster-Randomized Trials With Unequal Cluster Sizes (opens in a new tab)

  14. Non-Compliance in Clinical Trials: The Perils of Statistical Methods

    … most important deviations is non-compliance to treatment assignment. Intention to treat (ITT) is the most commonly employed method to deal with non-compliance in a clinical trial; however, it provides biased estimates of the effect of receiving the treatment. Other methods such as per protocol …

    uab Repository record for Non-Compliance in Clinical Trials: The Perils of Statistical Methods (opens in a new tab)

  15. Statistical Methods in Bioequivalence Studies

    Bioequivalence studies are an essential part of the evaluation of generic drugs. The most common in-vivo bioequivalence (BE) study design is the two-period two-treatment crossover design. AUC (area under the concentration-time curve) and Cmax (maximum concentration) are obtained from the observed …

    maryland Repository record for Statistical Methods in Bioequivalence Studies (opens in a new tab)

  16. Optimal and adaptive designs for multi-regional clinical trials with regional consistency requirement

    To shorten the time for drug development and regulatory approval, a growing number of clinical trials are being conducted in multiple regions simultaneously. One of the challenges to multi-regional clinical trials (MRCT) is how to utilize the data obtained from other regions within the entire trial …

    bu Repository record for Optimal and adaptive designs for multi-regional clinical trials with regional consistency requirement (opens in a new tab)

  17. Some recent advances in multivariate statistics: modality inference and statistical monitoring of clinical trials with multiple co-primary endpoints

    … statistics. The first part develops an inference procedure and fast computation tool for the modal clustering method proposed by Li et al. (2007). The modal clustering, based on the kernel density estimate, clusters data using their associations within a single mode, with the final number of …

    bu Repository record for Some recent advances in multivariate statistics: modality inference and statistical monitoring of clinical trials with multiple co-primary endpoints (opens in a new tab)

  18. BLINDED EVALUATIONS OF EFFECT SIZES IN CLINICAL TRIALS: COMPARISONS BETWEEN BAYESIAN AND EM ANALYSES

    Clinical trials are major and costly undertakings for researchers. Planning a clinical trial involves careful selection of the primary and secondary efficacy endpoints. The 2010 draft FDA guidance on adaptive designs acknowledges possible study design modifications, such as selection and/or order …

    temple Repository record for BLINDED EVALUATIONS OF EFFECT SIZES IN CLINICAL TRIALS: COMPARISONS BETWEEN BAYESIAN AND EM ANALYSES (opens in a new tab)

  19. Innovative Methods for the Design and Analysis of Phase II Clinical Trials

    Drug development has become increasingly time-consuming, costly, and risky in recent years. There is significant potential for improving clinical trial designs, particularly for phase II trials, which play a critical role in the drug development process. Innovative methods are especially necessary …

    uthsc Repository record for Innovative Methods for the Design and Analysis of Phase II Clinical Trials (opens in a new tab)

Page 1 of 2